Bristol Myers Squibb Company

BMY Healthcare Drug Manufacturers General

Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue grew 5.74%, EPS grew 153.1%, free cash flow fell 13.2% and total debt fell 12.3%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.

62.55 1.16 +1.89%
Market cap
$125.4B
P/E
13.8×
Fwd P/E
11.6×
Dividend yield
4.03%
F-score
8/9
Altman Z
2.14
Beneish M
−2.69
Dividend safety
63/100

Bristol Myers Squibb Company (BMY) EV/FCF

Alert me on EV/FCF

As of 30 October 2026, Bristol Myers Squibb Company (BMY) trades at a EV/FCF of 14.0×. Over the past ten years it has ranged from 7.8× (October 2025) to 389× (June 2016); the current reading is higher than 50% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2025 11.2× 1.97%
FY2024 11.0× 1.89%
FY2023 10.8× (29.85%)
FY2022 15.4× 41.26%
FY2021 10.9× (17.12%)
FY2020 13.2× (31.11%)
FY2019 19.1× 39.86%
FY2018 13.7× (43.53%)
FY2017 24.2× (55.32%)
FY2016 54.1× (40.63%)

Quarterly newest first

Period EV/FCF Change
Jun 2026 13.1× (1.10%)
Mar 2026 13.2× 17.92%
Dec 2025 11.2× 38.15%
Sep 2025 8.1× (8.76%)
42 more quarters

Against its own ten years

Low 7.8× High 389×
Ten-year median 14.0×
Current reading's percentile 55

EV/FCF against peers

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on BMY